Kiniksa Pharmaceuticals International Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
366
- Stock Symbol
-
KNSA
- Investments
-
2
- Share Price
-
$93.89
- (As of Friday Closing)
Kiniksa Pharmaceuticals International General Information
Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Contact Information
Website
www.kiniksa.comCorporate Office
- 100 Hayden Avenue
- Lexington, MA 02421
- United States
Corporate Office
- 100 Hayden Avenue
- Lexington, MA 02421
- United States
Kiniksa Pharmaceuticals International Stock Performance
As of 20-Nov-2026, Kiniksa Pharmaceuticals International’s stock price is $93.89. Its current market cap is $7.38B with 78.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $93.89 | $93.48 | $37.02 - $99.31 | $7.38B | 78.6M | 659K | $1.42 |
Kiniksa Pharmaceuticals International Financials Summary
As of 30-Sep-2026, Kiniksa Pharmaceuticals International has a trailing 12-month revenue of $946M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,304,341 | 2,784,191 | 1,214,962 | 1,045,615 |
| Revenue | 945,963 | 677,564 | 423,239 | 270,259 |
| EBITDA | 148,049 | 90,422 | (34,457) | (14,311) |
| Net Income | 109,568 | 59,005 | (43,193) | 14,084 |
| Total Assets | 983,243 | 763,633 | 580,553 | 526,322 |
| Total Debt | 7,884 | 9,497 | 9,855 | 12,258 |
Kiniksa Pharmaceuticals International Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kiniksa Pharmaceuticals International Comparisons
Industry
Financing
Details
Kiniksa Pharmaceuticals International Competitors (75)
One of Kiniksa Pharmaceuticals International’s 75 competitors is SpringWorks Therapeutics, a Formerly VC-backed company based in Stamford, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SpringWorks Therapeutics | Formerly VC-backed | Stamford, CT | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Santhera Pharmaceuticals Holding | Formerly VC-backed | Pratteln, Switzerland |
Kiniksa Pharmaceuticals International Signals
Kiniksa Pharmaceuticals International Investments & Acquisitions (2)
Kiniksa Pharmaceuticals International’s most recent deal was a Merger/Acquisition with Primatope Therapeutics for . The deal was made on 01-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Primatope Therapeutics | 01-Jan-2019 | Merger/Acquisition | Other Healthcare Services | ||
| Biogen (Biogen Assets in Cambridge, Massachusetts) | 01-Sep-2016 | Corporate Asset Purchase | Buildings and Property |
Kiniksa Pharmaceuticals International ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Kiniksa Pharmaceuticals International FAQs
-
When was Kiniksa Pharmaceuticals International founded?
Kiniksa Pharmaceuticals International was founded in 2015.
-
Where is Kiniksa Pharmaceuticals International headquartered?
Kiniksa Pharmaceuticals International is headquartered in Lexington, MA.
-
What is the size of Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International has 366 total employees.
-
What industry is Kiniksa Pharmaceuticals International in?
Kiniksa Pharmaceuticals International’s primary industry is Biotechnology.
-
Is Kiniksa Pharmaceuticals International a private or public company?
Kiniksa Pharmaceuticals International is a Public company.
-
What is Kiniksa Pharmaceuticals International’s stock symbol?
The ticker symbol for Kiniksa Pharmaceuticals International is KNSA.
-
What is the current stock price of Kiniksa Pharmaceuticals International?
As of 20-Nov-2026 the stock price of Kiniksa Pharmaceuticals International is $93.89.
-
What is the current market cap of Kiniksa Pharmaceuticals International?
The current market capitalization of Kiniksa Pharmaceuticals International is $7.38B.
-
What is Kiniksa Pharmaceuticals International’s current revenue?
The trailing twelve month revenue for Kiniksa Pharmaceuticals International is $946M.
-
Who are Kiniksa Pharmaceuticals International’s competitors?
SpringWorks Therapeutics, Aura Biosciences, Beam Therapeutics, Sarepta Therapeutics, and Santhera Pharmaceuticals Holding are some of the 75 competitors of Kiniksa Pharmaceuticals International.
-
What is Kiniksa Pharmaceuticals International’s annual earnings per share (EPS)?
Kiniksa Pharmaceuticals International’s EPS for 12 months was $1.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process